Successful rituximab therapy in a lupus patient with diffuse alveolar haemorrhage

Lupus

Volumn 20, Issue 6, 2011, Pages 656-659

  Pottier, V ^a   Pierrot, M ^a   Subra, J F ^a,b   Mercat, A ^a   Kouatchet, A ^a   Parrot, A ^c   Augusto, J F ^a,b  

^a ANGERS UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ D'ANGERS   (France)

^c HÔPITAL TENON   (France)

Author keywords

diffuse alveolar haemorrhage; mechanical ventilation; rituximab; systemic lupus erythematosus

Indexed keywords

ALBUMIN; ANTIBIOTIC AGENT; ANTINUCLEAR ANTIBODY; CD19 ANTIGEN; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; DNA ANTIBODY; HEMOGLOBIN; HYDROCORTISONE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NORADRENALIN; PHOSPHOLIPID ANTIBODY; PREDNISOLONE; PREDNISONE; RITUXIMAB;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; ARTIFICIAL VENTILATION; CASE REPORT; CORTICOSTEROID THERAPY; DIFFUSE ALVEOLAR HEMORRHAGE; DISEASE EXACERBATION; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FLUID RESUSCITATION; HEMOPTYSIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTENSIVE CARE UNIT; LUNG HEMORRHAGE; LUNG LAVAGE; MALE; PRIORITY JOURNAL; PULMONARY ARTERY OCCLUSION PRESSURE; SEPTIC SHOCK; SYSTEMIC LUPUS ERYTHEMATOSUS; THORAX RADIOGRAPHY;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; FEMALE; HEMORRHAGE; HUMANS; IMMUNOLOGIC FACTORS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PULMONARY ALVEOLI; TREATMENT OUTCOME;

EID: 79956118596     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203310386276     Document Type: Article

References (13)

1. Barile LA, Jara LJ, Medina-Rodriguez F, Garcia-Figueroa JL, Miranda-Limon JM. Pulmonary hemorrhage in systemic lupus erythematosus. Lupus. 1997 ; 6: 445-448 (Pubitemid 27395382)
2. Badsha H, Teh CL, Kong KO, Lian TY, Chng HH. Pulmonary hemorrhage in systemic lupus erythematosus. Semin Arthritis Rheum. 2004 ; 33: 414-421 (Pubitemid 38887140)
3. Malik SW, Myers JL, DeRemee RA, Specks U. Lung toxicity associated with cyclophosphamide use. Two distinct patterns. Am J Respir Crit Care Med. 1996 ; 154: 1851-1856 (Pubitemid 26424960)
4. Haupt HM, Moore GW, Hutchins GM. The lung in systemic lupus erythematosus. Analysis of the pathologic changes in 120 patients. Am J Med. 1981 ; 71: 791-798 (Pubitemid 12192356)
5. Zandman-Goddard G, Ehrenfeld M, Levy Y, Tal S. Diffuse alveolar hemorrhage in systemic lupus erythematosus. Isr Med Assoc J. 2002 ; 4: 470-470
6. Garcia-Carrasco M, Jimenez-Hernandez M, Escarcega RO, et al. Use of rituximab in patients with systemic lupus erythematosus: an update. Autoimmun Rev. 2009 ; 8: 343-348
7. Smith KG, Jones RB, Burns SM, Jayne DR. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment. Arthritis Rheum. 2006 ; 54: 2970-2982 (Pubitemid 44497778)
8. Lee JW, Kim HA, Sung JM, Suh CH. Successful treatment of refractory immune thrombocytopenia with anti-CD20 antibody in a patient with systemic lupus erythematosus. Lupus. 2009 ; 19: 227-228
9. Nellessen CM, Poge U, Brensing KA, Sauerbruch T, Klehr HU, Rabe C. Diffuse alveolar haemorrhage in a systemic lupus erythematosus patient successfully treated with rituximab: a case report. Nephrol Dial Transplant. 2008 ; 23: 385-386 (Pubitemid 351767423)
10. Narshi CB, Haider S, Ford CM, Isenberg DA, Giles IP. Rituximab as early therapy for pulmonary haemorrhage in systemic lupus erythematosus. Rheumatology (Oxford). 2009 ; 49: 392-394
11. Ahmed AR, Hombal SM. Cyclophosphamide (Cytoxan). A review on relevant pharmacology and clinical uses. J Am Acad Dermatol. 1984 ; 11: 1115-1126 (Pubitemid 15210494)
12. Cambridge G, Leandro MJ, Teodorescu M, et al. B cell depletion therapy in systemic lupus erythematosus: effect on autoantibody and antimicrobial antibody profiles. Arthritis Rheum. 2006 ; 54: 3612-3622 (Pubitemid 44737173)
13. Arzoo K, Sadeghi S, Liebman HA. Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab). Ann Rheum Dis. 2002 ; 61: 922-924